RITUXAN HYCELA
PeakmAbBLASUBCUTANEOUSSOLUTION
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RITUXAN HYCELA is a subcutaneous formulation combining rituximab (a CD20-directed monoclonal antibody) with hyaluronidase, enabling subcutaneous delivery of this established B-cell lymphoma and autoimmune therapy. The hyaluronidase enzyme facilitates subcutaneous administration by temporarily breaking down hyaluronic acid in subcutaneous tissue, improving drug distribution and patient convenience. This formulation maintains the well-established anti-CD20 mechanism while eliminating the need for intravenous infusion.
$0.638MPart D
PeakProduct is in peak lifecycle phase, indicating mature commercialization with stable team structure and focus on market defense rather than aggressive expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RITUXAN HYCELA offers career stability in a peak-stage asset where success depends on defensive market positioning, payer relationships, and patient adherence to subcutaneous administration. Roles emphasize lifecycle management, competitive intelligence, and reimbursement strategy rather than launch intensity, making this suitable for experienced professionals seeking steady-state brand management.
Brand Manager
Worked on RITUXAN HYCELA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.